1 results match your criteria: "Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc[Affiliation]"
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Clin Cancer Res
March 2007
Institute for Myeloma and Bone Cancer Research and Oncotherapeutics Inc, West Hollywood, CA 90069, USA.
Purpose: This multicenter, open-label, phase I/II dose escalation study assessed the safety/tolerability and initial efficacy of arsenic trioxide/bortezomib/ascorbic acid (ABC) combination therapy in patients with relapsed/refractory multiple myeloma.
Experimental Design: Enrolled in six cohorts, patients were given arsenic trioxide (0.125 or 0.